GSK Annual Report 2011 235 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Pharmaceuticals and Vaccines product development pipeline Key MAA Marketing Authorisation Application Europe In-license or other alliance relationship with third party NDA New Drug Application USA S Month of first submission PO Month of EU positive opinion A Month of first regulatory approval for MAA, this is the first EU Phase I Evaluation of clinical pharmacology, usually conducted in volunteers approval letter Phase II Determination of dose and initial evaluation of efcacy, conducted in a CR Month Complete Response Letter received indicates small number of patients that ultimately approval may be given subject to resolution of Phase III Large comparative study compound versus placebo and or established outstanding queries treatment in patients to establish clinical benefit and safety BLA Biological License Application MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future ling dates are not included in this list.
Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Biopharmaceuticals 1070806 IL18 monoclonal antibody type 2 diabetes & inammatory bowel disease I 1223249 neurite outgrowth inhibitor NOGO-A amyotrophic lateral sclerosis & multiple sclerosis I monoclonal antibody 1995057 tumour necrosis factor receptor-1 TNFR1 acute lung injury I domain antibody 2374697 glucagon like peptide-1 GLP 1 agonist with obesity I half-life improving domain antibody 2586881 recombinant human angiotensin converting acute lung injury I enzyme 2 2661380 AMP-244 immunomodulator solid tumours I otelixizumab CD3 monoclonal antibody s. c. & i. v. rheumatoid arthritis I 249320 myelin-associated glycoprotein monoclonal stroke II antibody 933776 beta amyloid monoclonal antibody geographic retinal atrophy II albiglutide GLP 1 agonist heart failure II mepolizumab IL5 monoclonal antibody severe asthma & nasal polyposis II ofatumumab CD20 human monoclonal antibody s. c. multiple sclerosis II ofatumumab CD20 human monoclonal antibody s. c. rheumatoid arthritis II sirukumab IL6 human monoclonal antibody s. c. rheumatoid arthritis II albiglutide GLP 1 agonist type 2 diabetes III Arzerra ofatumumab CD20 human monoclonal antibody chronic lymphocytic leukaemia, first line therapy & use III in relapsed patients Arzerra ofatumumab CD20 human monoclonal antibody diffuse large B cell lymphoma relapsed patients III Arzerra ofatumumab CD20 human monoclonal antibody follicular lymphoma refractory & relapsed patients III Benlysta belimumab B lymphocyte stimulator monoclonal systemic lupus erythematosus III antibody s. c. Benlysta belimumab B lymphocyte stimulator monoclonal systemic lupus erythematosus Approved A: Jul11 A: Mar11 antibody i. v. Xgeva denosumab receptor activator for nuclear kappa RANK bone metastatic disease Approved N A N A ligand human monocional antibody Cardiovascular & Metabolic 1614235 sodium dependent glucose transport SGLT1 type 2 diabetes I inhibitor 2330672 ileal bile acid transfer inhibitor type 2 diabetes I 256073 high afnity nicotinic acid receptor HM74A metabolic disorders II agonist 962040 motilin receptor agonist delayed gastric emptying II 1278863 prolyl hydroxylase inhibitor peripheral arterial disease II 1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II losmapimod p38 kinase inhibitor acute coronary syndrome also COPD II retosiban oxytocin antagonist threatened pre-term labour II ronacaleret calcium receptor antagonist allogeneic haematopoietic stem cell mobilisation II darapladib Lp-PLA2 inhibitor atherosclerosis also diabetic macular oedema III Immuno-inammation 705498 transient receptor potential vanilloid TRPV1 pruritis I antagonist topical 2586184 signalling inhibitor systemic lupus erythematosus I 1399686 anti-inammatory macrolide conjugate oral inammatory bowel disease II 2245840 SIRT1 activator psoriasis II 2941266 CCX354 CCR1 chemokine receptor antagonist rheumatoid arthritis II 1605786 CCR9 chemokine receptor antagonist Crohn's disease III 236 GSK Annual Report 2011 Shareholder Pipeline continued information Pharmaceuticals and Vaccines product development pipeline Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Infectious Diseases 2140944 type 2 topoisomerase inhibitor bacterial infections I 2251052 leucyl t-RNA synthetase inhibitor oral bacterial infections I 1322322 polypeptide deformylase inhibitor bacterial infections II 2251052 leucyl t-RNA synthetase inhibitor i. v. bacterial infections II 2336805 hepatitis C virus inhibitor hepatitis C II tafenoquine 8-aminoquinoline Plasmodium vivax malaria II Relenza i. v. zanamivir neuraminidase inhibitor i. v. inuenza III Neurosciences 356278 phoshodiesterase 4 inhibitor Huntington's Disease I 649868 orexin antagonist sleep disorders II 742457 5HT6 antagonist dementia II rategrast dual alpha 4 integrin antagonist VLA4 multiple sclerosis II rilapladib Lp-PLA2 inhibitor Alzheimers disease II 587124 IPX066 dopamine precursor DOPA decarboxylase Parkinson's disease III N A inhibitor Horizant gabapentin voltage-gated calcium channel modulator post-herpetic neuralgia Submitted N A S: Aug11 enacarbil Horizant gabapentin voltage-gated calcium channel modulator restless legs syndrome Approved N A A: Apr11 enacarbil Trobalt Potiga neuronal potassium channel opener epilepsy, partial seizures Approved A: Mar11 A: Jun11 retigabine ezogabine Oncology 2110183 AKT protein kinase inhibitor cancer I 2256098 focal adhesion kinase inhibitor cancer I 2636771 phosphatidylinositol 3-kinase PI3K inhibitor cancer I trametinib 1120212 mitogen-activated protein kinase inhibitor cancer I BKM120 MEK1 2 PI3K inhibitor vestipitant neurokinin-1 antagonist i. v. post operative nausea & vomiting I 2110183 AKT protein kinase inhibitor Langerhan cell histiocytosis II dabrafenib 2118436 BRaf protein kinase inhibitor non-small cell lung cancer II foretinib  transition factor papillary renal cell carcinoma and other cancers II C-met kinase inhibitor Revolade Promacta thrombopoietin receptor agonist  thrombocytopaenia II eltrombopag trametinib 1120212 MEK1 2 inhibitor KRAS mutant non-small cell lung cancer, second line II therapy trametinib 1120212 MEK1 2 inhibitor pancreatic cancer, first line therapy II trametinib 1120212 MEK1 2 inhibitor AKT protein kinase cancer II 2110183 inhibitor trametinib 1120212 MEK1 2 inhibitor BRaf protein kinase metastatic melanoma II dabrafenib 2118436 inhibitor dabrafenib 2118436 BRaf protein kinase inhibitor metastatic melanoma III trametinib 1120212 MEK1 2 inhibitor metastatic melanoma III Revolade Promacta thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia III eltrombopag Tyverb Tykerb lapatinib human epidermal growth factor receptor-2 breast cancer, adjuvant therapy III Her2 and epidermal growth factor receptor EGFR dual kinase inhibitor Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor gastric cancer III Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor head & neck squamous cell carcinoma resectable disease III Votrient pazopanib multi-kinase angiogenesis inhibitor ovarian cancer, maintenance therapy III Votrient pazopanib multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy III Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor metastatic breast cancer, in combination with trastuzumab Submitted S: Feb12 S: Feb12 Votrient pazopanib multi-kinase angiogenesis inhibitor sarcoma Submitted S: Jul11 S: Jun11 Ophthalmology darapladib Lp-PLA2 inhibitor diabetic macular oedema also atheroscierosis II pazopanib multi-kinase angiogenesis inhibitor age-related macular degeneration also cancer II eye drops indications GSK Annual Report 2011 237 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Pharmaceuticals and Vaccines product development pipeline Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory & Immuno-inammation 1325756 CXCR2 chemokine receptor antagonist COPD I 1440115 urotensin antagonist asthma I 2245035 toll-like receptor 7 agonist asthma I 2269557 phosphoinositide 3 kinase inhibitor asthma I 2339345 sodium channel blocker cough I 961081 muscarinic antagonist, beta2 agonist COPD II 2190915  protein FLAP asthma II inhibitor dilmapimod 681323 p38 kinase inhibitor i. v. acute lung injury & acute respiratory distress syndrome II losmapimod p38 kinase inhibitor oral COPD also cardiovascular disease II 573719 muscarinic acetylcholine antagonist COPD III 573719 vilanterol muscarinic acetylcholine antagonist longCOPD III acting beta2 agonist 685698 glucocorticoid agonist asthma III vilanterol long-acting beta2 agonist COPD III Relovair long-acting beta2 agonist glucocorticoid asthma III vilanterol 685698 agonist Relovair long-acting beta2 agonist glucocorticoid COPD III vilanterol 685698 agonist Paediatric Vaccines Malaria NG Pf improved recombinant malaria prophylaxis Plasmodium falciparum I MMR live attenuated measles, mumps, rubella prophylaxis II US A: Nov97 S. pneumoniae paediatric recombinant - conjugated Streptococcus pneumoniae disease prophylaxis II next generation Mosquirix Malaria RTS, S recombinant malaria prophylaxis Plasmodium falciparum III N A MenHibrix Hib-MenCY-TT conjugated Neisseria meningitis groups C & Y & Haemophilus inuenzae Submitted N A CR: Sep11 type b disease prophylaxis Nimenrix MenACWY-TT conjugated Neisseria meningitis groups A, C, W & Y disease prophylaxis Submitted S: Mar11 II, US Other Vaccines Flu pandemic cell-culture based H5N1 vaccine pandemic inuenza prophylaxis I Staphylococcus Aureus recombinant conjugated Staphylococcus aureus prophylaxis I HIV recombinant HIV disease prophylaxis I HIV recombinant HIV disease immunotherapy II Tuberculosis recombinant tuberculosis prophylaxis II Zoster recombinant Herpes Zoster prevention III Flu prepandemic H5N1 inactivated split monovalent Quebec pre-pandemic & pandemic inuenza prophylaxis Submitted N A S:Jun09 Canada Flu vaccine inactivated split quadrivalent seasonal inuenza prophylaxis Submitted S: Feb12 Pumarix H5N1 inactivated split monovalent Quebec pandemic inuenza prophylaxis Approved A: Mar11 N A Antigen Specic Cancer Immunotherapeutic ASCI NY-ESO-1 recombinant treatment of metastatic melanoma I PRAME recombinant treatment of metastatic melanoma I PRAME recombinant treatment of resectable non-small cell lung cancer I WT1 recombinant treatment of breast cancer I WT1 recombinant treatment of acute myelogenous leukaemia II MAGE-A3 recombinant treatment of bladder cancer II MAGE-A3 recombinant treatment of melanoma III MAGE-A3 recombinant treatment of non-small cell lung cancer III 238 GSK Annual Report 2011 Shareholder Pipeline continued information Pharmaceuticals and Vaccines product development pipeline Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Rare Diseases 2402968 antisense oligonucleotide Duchenne muscular dystrophy III 2696273 ex-vivo stem cell gene therapy adenosine deaminase severe combined immune deficiency III ADA-SCID migalastat HCl pharmacological chaperone Fabry disease III Stiefel late-stage assets only 870086 novel glucocorticoid agonist topical atopic dermatitis II Duac low dose clindamycin benzoyl peroxide gel acne vulgaris Submitted S: Nov11 S: Nov10 Sorilux vitamin D3 analog scalp psoriasis Submitted S: Nov11 calcipotriene foam tazarotene foam retinoid foam acne vulgaris Submitted S: Jul11 HIV ViiV Healthcare S GSK1265744 HIV integrase inhibitor long-acting parenteral HIV infections I formulation lersivirine UK-453061 non-nucleoside reverse transcriptase inhibitor HIV infections II dolutegravir HIV integrase inhibitor HIV infections III S GSK1349572 dolutegravir HIV integrase inhibitor reverse transcriptase HIV infections III S GSK1349572 inhibitors xed dose combination abacavir sulphate lamivudine Brand names appearing in italics are trademarks either owned by and or licensed to GlaxoSmithKline or associated companies.
Option-based alliances with third parties that include assets in Phase I or later development: Company Disease Area Phase Cancer Research UK I cancer ChemoCentryx II inammatory disease Concert Pharmaceuticals I HIV Dynavax Technologies II cutaneous & systemic lupus erythematosus ISIS Pharmaceuticals I  amyloidosis OncoMed Pharmaceuticals I oncology Prosensa Therapeutics II neuroscience Ranbaxy Laboratories II respiratory Telethon Institute for Gene Therapy II stem cell gene therapy Afris Alzheimers disease treatment vaccine II Nabi III nicotine vaccine CCX168 Two assets GSK Annual Report 2011 239 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Pharmaceutical products, competition and intellectual property Major Patent expiry dates Products Compounds Indication s competitor brands USA EU Respiratory Veramyst uticasone propionate rhinitis COPD Nasacort 2021 2023 Flixotide Flovent uticasone propionate asthma COPD Qvar, Singulair expired expired compound compound 2016 expired Diskus device Diskus device 2013-2025 2012-2017 HFA-device HFA-device formulation formulation 1 Seretide Advair salmeterol xinafoat asthma COPD Singulair, Symbicort, expired 2013 uticasone propionate Spiriva, Asmanex, combination combination Pulmicort, Foster 2016 expired Diskus device Diskus device 2013-2025 2012-2017 HFA-device HFA-device formulation formulation Serevent salmeterol xinafoate asthma COPD Foradil, Spiriva expired expired compound compound 2016 expired Diskus device Diskus device NA 2012-2019 HFA-device formulation Ventolin HFA albuterol sulphate asthma COPD generic companies 2015-2025 2012-2017 HFA-device HFA-device formulation formulation Anti-virals Relenza zanamivir inuenza Tamiu 2013 2014 Valtrex valaciclovir genital herpes, coldsores, Famvir expired expired shingles Zefx Epivir-HBV lamivudine chronic hepatitis B Hepsera 2014 expired use use Central nervous system Lamictal lamotrigine epilepsy, bipolar disorder Keppra, Dilantin expired expired Imigran Imitrex sumatriptan migraine Zomig, Maxalt, Relpax expired expired Requip XL ropinirole Parkinsons disease Mirapex 2012 expired formulation Seroxat Paxil paroxetine depression, various Effexor, Cymbalta, expired expired anxiety disorders Lexapro Treximet sumatriptan and naproxen migraine Zomig, Maxalt, 2017 NA Relpax combination and use Wellbutrin bupropion depression Effexor, Cymbalta, expired expired Lexapro Cardiovascular and urogenital Arixtra fondaparinux deep vein thrombosis, Lovenox, Fragmin expired expired pulmonary embolism Innohep 1 Avodart dutasteride benign prostatic hyperplasia Proscar, Flomax, 2015 2017 nasteride Benlysta belimumab systemic lupus erychematosus 2023 2021 Coreg CR carvedilol phosphate mild-to-severe heart failure, Toprol XL 2016 NA hypertension, left ventricular formulation dysfunction post MI Fraxiparine nadroparin deep vein thrombosis, Lovenox, Fragmin expired expired pulmonary embolism Innohep See Outlook on page 15 for details of uncertainty on the timing of follow-on competition.
240 GSK Annual Report 2011 Shareholder Shareholder information continued information Pharmaceutical products, competition and intellectual property Major Patent expiry dates Products Compounds Indication s competitor brands USA EU 1 Lovaza omega-3 acid ethyl esters very high triglycerides Tricor 2017 NA formulation Volibris ambrisentan pulmonary hypertension Tracleer, Revatio NA 2020 Anti-bacterials Augmentin amoxicillin clavulanate common bacterial generic products NA expired potassium infections Oncology Arzerra ofatumumab refractory chronic MabThera Rituxan pending 2023 lymphocytic leukaemia Hycamtin topotecan ovarian cancer, small cell Doxil, Gemzar expired expired lung cancer, cervical cancer Promacta eltrombopag idiopathic thrombocytopenic Nplate 2021 2021 Revolade purpura Tykerb Tyverb lapatanib advanced and metastatic Herceptin 2020 2023 breast cancer in HER2 positive patients Votrient pazopanib metastatic renal cell carcinoma Sutent, Nexavar, 2021 2021 Anitor Vaccines Boostrix diphtheria, tetanus, acellular booster vaccination Adacel 2017 2017 pertussis Infanrix Pediarix diphtheria, tetanus, pertussis, diphtheria, tetanus, pertussis, Pentacel, Pediacel, 2017 2014 polio, hepatitis B HepB, polio, hepatitis B HepB Pentaxim, Pentavac inactivated antigens Cervarix HPV 16 & 18 virus like particles human papilloma virus Gardasil Silgard 2020 2020 VLPs, AS04 adjuvant MPL type 16 & 18 aluminium hydroxide Fluarix split inactivated inuenza virus seasonal inuenza Vaxigrip, Mutagrip, 2022 2022 subtypes A and type B antigens Fluzone, Inuvac, Aggripal, Fluad FluLaval split inactivated inuenza virus seasonal inuenza Vaxigrip, Mutagrip, none none subtypes A and type B antigens Fluzone, Inuvac, Aggripal, Fluad Pandemrix derived split inactivated A H1N1 v2009 inuenza Focetria, Celvapan, 2014 2014 inuenza virus antigen, prophylaxis emeru AS03 adjuvant Prepandrix derived split inactivated inuenza prophylaxis Aunov 2014 2014 inuenza virus antigen, AS03 adjuvant Synorix conjugated pneumococcal invasive pneumococcal Prevenar Prevnar NA 2021 polysaccharide disease HIV 2 Combivir lamivudine and zidovudine HIV AIDS Truvada, Atripla 2012 2013 combination combination Epivir lamivudine HIV AIDS Truvada, Atripla expired expired 1 Epzicom Kivexa lamivudine and abacavir HIV AIDS Truvada, Atripla 2016 2019 combination combination Lexiva fosamprenavir HIV AIDS Prezista, Kaletra, 2017 2019 Reyataz Selzentry maraviroc HIV AIDS Isentress, Intelence, 2021 2022 Prezista 1 Trizivir lamivudine, zidovudine HIV AIDS Truvada, Atripla 2016 2016 and abacavir combination combination 1 See Note 44 to the financial statements, Legal proceedings.
GSK Annual Report 2011 241 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Consumer Healthcare products, competition and intellectual property Brand Products Application Markets Competition Oral healthcare Sensodyne toothpastes, toothbrushes prevention of dental global Colgate-Palmolives mouthwashes sensitivity Colgate Pro Relief Polident denture adhesive, denture improve comfort of global none globally Poligrip cleanser tted dentures and to Corega clean dentures Aquafresh toothpastes, toothbrushes prevention of caries, gum global Colgate-Palmolives Colgate, disease and bad breath Procter & Gambles Crest OTC medicines Panadol tablets, capulets, infant drops paracetamol-based treatment global, except USA Reckitt-Benckisers Nurofen of headache and joint pain, fever, cold symptoms NicoDerm, gum, patch, mini lozenge, treatment of nicotine global Novartis Nicotinell, NiQuitin CQ, original lozenge withdrawal as an aid to Nicorette in Europe, and Nicabate.
quitting smoking retailers own brands Also Nicorette USA only Nutritional healthcare Lucozade energy and sports drinks energy and hydration UK, Ireland, some Pepsicos Gatorade, other markets Coca-Colas Powerade, Red Bull Horlicks malted, milk-based drinks nutrition UK, Ireland, India Krafts Bournvita, and foods Nestles Milo
